AC Immune (ACIU) Gains from Investment Securities (2018 - 2021)
AC Immune (ACIU) posted quarterly Gains from Investment Securities of -$36900.4 for Q2 2019, up 99.18% quarter-over-quarter from -$4.5 million in Q1 2019.
Powered by 
Analysis
AC Immune (ACIU) Gains from Investment Securities (2018 - 2021) Analysis & Trends
AC Immune (ACIU) has reported Gains from Investment Securities for 1 consecutive years, with -$36900.4 the latest figure, recorded in Q2 2019.
- In Q2 2019, Gains from Investment Securities changed N/A year-over-year to -$36900.4; the TTM figure through Sep 2025 stood at -$36900.4 (changed N/A YoY), while the FY2025 annual figure was -$18091.9, changed N/A from the prior year.
- Gains from Investment Securities rose to -$36900.4 in Q2 2019 per ACIU's latest filing, from -$4.5 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at -$36900.4 in Q2 2019 and bottomed at -$4.5 million in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | AC Immune | 285.13 Mn | 285.13 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | -705,665.68 |
| Sep 30, 2020 | 127,104.76 |
| Jun 30, 2020 | -156,709.59 |
| Mar 31, 2020 | 447,655.58 |
| Sep 30, 2019 | -332,904.05 |
| Jun 30, 2019 | 1.56 Mn |
| Mar 31, 2019 | 80,325.00 |
| Sep 30, 2018 | 1.37 Mn |
| Jun 30, 2018 | -431,780.86 |
| Mar 31, 2018 | 307,886.59 |